Pharmacology: Allylestrenol stimulates placental progesterone production in vitro and increases placental hormone secretion (human chorionic gonadotrophin, human placental lactogen, oestrogen and progesterone) and oxytocinase in patients with pregnancy risks. Accordingly, placental trophoblastic layer shows signs of histologic activities. Clinical study showed that allylestrenol is an effective substance to maintain pregnancy. Administration of allylestrenol and bedrest may eliminate threatened abortion at the early stage of pregnancy or threatened premature labor. Pregnolin is well tolerated.
Threatened abortion. Habitual abortion. Threatened premature labor.
Threatened Abortion: 1 tab 3 times daily for 5-7 days. Therapy may be prolonged if required. Dosage should be gradually reduced after symptoms disappear unless symptoms reappear.
Habitual Abortion: 1-2 tabs daily immediately after pregnancy is detected. Therapy should be continued for at least 1 month after critical period is over.
Threatened Premature Labor: Dosage is determined individually. High doses up to 40 mg/day have been used.
Monitor patients with diabetes during therapy. Discontinue therapy if the following occurs: Visual disturbances, proptosis or diplopia, vascular retinal ulcer and migraine.
Gastrointestinal Disturbances: Nausea and vomiting.
Serious reactions have not been reported from mothers and their newborns.
G03DC01 - allylestrenol ; Belongs to the class of estren derivative progestogens used in progestogenic hormone preparations.
Chewable tab 5 mg x 50's.